{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-010634","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.711255+00:00","generated_at":"2026-05-15T08:06:57.473884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed","bullets":["Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).","Closed zaltenibart deal with Novo Nordisk Nov 2025, receiving $240M upfront; repaid $67.1M term loan and $17.1M convertible notes.","FDA approved YARTEMLEA (narsoplimab) for TA-TMA Dec 2025; commercial launch began Jan 2026.","Q4 OMIDRIA royalties $9.2M on $30.7M net sales vs. $10.1M on $33.6M in prior year.","Operating expenses fell to $122.8M in FY25 from $167.0M in FY24, down $44.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-010634","json":"https://secwatch.observer/filing/0001437749-26-010634.json","markdown":"https://secwatch.observer/filing/0001437749-26-010634.md","text":"https://secwatch.observer/filing/0001437749-26-010634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/0001437749-26-010634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/omer20251116_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:06:57.473884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52727b12429edbeff31c7c1d4f1cd0a0d16fc670","claim":"OMEROS CORP reported fourth quarter and year ended December 31, 2025 results: net income Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, EPS Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million.","evidence_excerpt":"Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results – Conference Call Today at 4:30 p.m. ET","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/0001437749-26-010634-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2025"},{"label":"Net income","value":"Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million"},{"label":"EPS","value":"Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}